Patent classifications
C07C255/61
N-(2-FLUORO-2-PHENETHYL)CARBOXAMIDES AS NEMATICIDES AND ENDOPARASITICIDES
The present invention relates to N-(2-halogen-2-phenethyl)carboxamides, a process for producing such compounds, their use for the control of nematodes in agricultures and their use as anthelmintics against endoparasites in animals or humans, compositions containing such compounds and methods for the control of nematodes and helminths.
N-(2-FLUORO-2-PHENETHYL)CARBOXAMIDES AS NEMATICIDES AND ENDOPARASITICIDES
The present invention relates to N-(2-halogen-2-phenethyl)carboxamides, a process for producing such compounds, their use for the control of nematodes in agricultures and their use as anthelmintics against endoparasites in animals or humans, compositions containing such compounds and methods for the control of nematodes and helminths.
SPIRALLY CONFIGURED CIS-STILBENE/FLUORENE HYBRID MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME
A spirally configured cis-stilbene/fluorene hybrid material is shown in formula (1),
##STR00001##
R is an alkyl group or represented by formula (2),
##STR00002##
wherein R.sub.1 to R.sub.4, R.sub.6, R.sub.8 to R.sub.11 and R.sub.13 to R.sub.18 are independently selected from the group consisting of hydrogen atom, halogen atom, cyano group, alkyl group, cycloalkyl group, alkoxy group, amino group, haloalkyl group, thioalkyl group, silyl group and alkenyl group, R.sub.5 is a hydrogen atom, tert-butyl group or aryl group, R.sub.7 and R.sub.12 are independently selected from the group consisting of hydrogen atom, aryl group, diarylamino group, cyano group, heteroaryl (e.g., pyridine group, or pyrimidine group).
SPIRALLY CONFIGURED CIS-STILBENE/FLUORENE HYBRID MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME
A spirally configured cis-stilbene/fluorene hybrid material is shown in formula (1),
##STR00001##
R is an alkyl group or represented by formula (2),
##STR00002##
wherein R.sub.1 to R.sub.4, R.sub.6, R.sub.8 to R.sub.11 and R.sub.13 to R.sub.18 are independently selected from the group consisting of hydrogen atom, halogen atom, cyano group, alkyl group, cycloalkyl group, alkoxy group, amino group, haloalkyl group, thioalkyl group, silyl group and alkenyl group, R.sub.5 is a hydrogen atom, tert-butyl group or aryl group, R.sub.7 and R.sub.12 are independently selected from the group consisting of hydrogen atom, aryl group, diarylamino group, cyano group, heteroaryl (e.g., pyridine group, or pyrimidine group).
Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same
The present invention includes substituted 3,3bis(phenoxymethyl)-1,1-biphenyl compounds, analogues thereof, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in a patient.
Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same
The present invention includes substituted 3,3bis(phenoxymethyl)-1,1-biphenyl compounds, analogues thereof, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in a patient.
Polymers functionalized with protected oxime compounds containing a cyano group
A method for preparing a functionalized polymer, the method comprising the steps of: (i) polymerizing monomer to form a reactive polymer, and (ii) reacting the reactive polymer with a protected oxime compound containing a cyano group.
Polymers functionalized with protected oxime compounds containing a cyano group
A method for preparing a functionalized polymer, the method comprising the steps of: (i) polymerizing monomer to form a reactive polymer, and (ii) reacting the reactive polymer with a protected oxime compound containing a cyano group.
Synthesis of an antiviral compound
- Amy Cagulada ,
- Johann Chan ,
- Lina Chan ,
- Denise A. Colby ,
- Kapil Kumar Karki ,
- Darryl Kato ,
- Katie Ann Keaton ,
- Sudha Kondappally ,
- Chris Levins ,
- Adam Littke ,
- Ruben Martinez ,
- Dominika Pcion ,
- Troy Reynolds ,
- Bruce Ross ,
- Michael Sangi ,
- Adam J. Schrier ,
- Pamela Seng ,
- Dustin Siegel ,
- Nathan Shapiro ,
- Donald Tang ,
- James G. Taylor ,
- Jonathan Tripp ,
- Andrew W. Waltman ,
- Lawrence Yu
The present disclosure provides processes for the preparation of a compound of formula I: ##STR00001##
which is useful as an antiviral agent. The disclosure also provides compounds and processes for the preparation of the compounds that are synthetic intermediates to the compound of formula I.
Synthesis of an antiviral compound
- Amy Cagulada ,
- Johann Chan ,
- Lina Chan ,
- Denise A. Colby ,
- Kapil Kumar Karki ,
- Darryl Kato ,
- Katie Ann Keaton ,
- Sudha Kondappally ,
- Chris Levins ,
- Adam Littke ,
- Ruben Martinez ,
- Dominika Pcion ,
- Troy Reynolds ,
- Bruce Ross ,
- Michael Sangi ,
- Adam J. Schrier ,
- Pamela Seng ,
- Dustin Siegel ,
- Nathan Shapiro ,
- Donald Tang ,
- James G. Taylor ,
- Jonathan Tripp ,
- Andrew W. Waltman ,
- Lawrence Yu
The present disclosure provides processes for the preparation of a compound of formula I: ##STR00001##
which is useful as an antiviral agent. The disclosure also provides compounds and processes for the preparation of the compounds that are synthetic intermediates to the compound of formula I.